TIL Therapy – Pipeline Insight, 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “TIL Therapy – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in TIL Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Companies Mentioned

• Ivoance Biotherapeutics
• Instil Bio
• Lion Biotechnologies
• Turnstone Biologics
• Nurix therapeutics
• Lytix Biopharma
• Cellular Biomedicine Group, Inc
• KSQ Therapeutics
• AgonOx, Inc.
• TILT Biotherapeutics
• Achilles therapeutics

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence TIL Therapy R&D. The therapies under development are focused on novel approaches to treat/improve TIL Therapy.

TIL Therapy Emerging Drugs Chapters

This segment of the TIL Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TIL Therapy Emerging Drugs

LN-145: Ivonace Biotherapeutics

The TIL therapy under investigation in Phase II clinical trial, lifileucel (formerly LN-145), is expanded and rejuvenated TIL that was extracted from the patient’s own tumor. Lifileucel is an investigational therapy that is being tested in clinical studies for the treatment of Recurrent, Metastatic or Persistent Cervical Carcinoma.

ITIL-168: Instil Bio

ITIL-68 has been designed to improve the scalability, logistics, and accessibility of TIL therapy. The drug is currently in phase I stage of development for the treatment of patients with Melanoma.

TIL Therapy: Therapeutic Assessment

This segment of the report provides insights about the different TIL Therapy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in TIL Therapy

There are approx. 30+ key companies which are developing the therapies for TIL Therapy. The companies which have their TIL Therapy drug candidates in the most advanced stage, i.e. phase II include, Ivonace Biotherapeutics.

Phases

This report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

TIL Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TIL Therapy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TIL Therapy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIL Therapy drugs.

TIL Therapy Report Insights

• TIL Therapy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

TIL Therapy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing TIL Therapy drugs?
• How many TIL Therapy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TIL Therapy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the TIL Therapy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for TIL Therapy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Topics Covered:

1. Introduction

2. Executive Summary

3. TIL Therapy: Overview

• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management

4. Pipeline Therapeutics

• Comparative Analysis

5. Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

6. TIL Therapy – Analytical Perspective

7. In-depth Commercial Assessment

• TIL Therapy companies’ collaborations, Licensing, Acquisition -Deal Value Trends

8. TIL Therapy Collaboration Deals

• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis

9. Mid Stage Products (Phase II)

• Comparative Analysis

10. LN-145: Ivonace Biotherapeutics

• Product Description
• Research and Development
• Product Development Activities

11. Early Stage Products (Phase I)

• Comparative Analysis

12. ITIL-168: Instil Bio

• Product Description
• Research and Development
• Product Development Activities

13. Inactive Products

• Comparative Analysis

14. TIL Therapy Key Companies

15. TIL Therapy Key Products

16. TIL Therapy- Unmet Needs

17. TIL Therapy- Market Drivers and Barriers

18. TIL Therapy- Future Perspectives and Conclusion

19. TIL Therapy Analyst Views

20. TIL Therapy Key Companies

21. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ya4lej

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900